You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Mallinckrodt
Express Scripts
Baxter
Moodys

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OPSUMIT

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Opsumit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02050802 Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects Completed Actelion Phase 1 2011-08-01 The study is intended to demonstrate that macitentan does not have an effect on cardiac repolarization exceeding the threshold of regulatory concern after repeated administration of daily oral doses of 10 and 30 mg to healthy male and female subjects.
NCT02126943 OPsumit USers Registry Recruiting Actelion N/A 2014-04-01 Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
NCT02476864 Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults Completed Actelion Phase 1 2015-08-01 A study conducted in healthy adults to investigate if a new macitentan tablet leads to the same fate of macitentan in the body (time of onset, time of presence, amount in the blood) as the marketed macitentan tablet.
NCT02651272 Macitentan in Pulmonary Hypertension of Sickle Cell Disease Recruiting Actelion Phase 1 2015-07-01 This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
NCT02651272 Macitentan in Pulmonary Hypertension of Sickle Cell Disease Recruiting Boston University Phase 1 2015-07-01 This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
NCT02885012 Crossover Study From Macitentan or Bosentan Over to Ambrisentan Recruiting Ochsner Health System Phase 4 2016-06-01 The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease associated Pulmonary Arterial Hypertension (CTD-PAH).
NCT02885012 Crossover Study From Macitentan or Bosentan Over to Ambrisentan Recruiting Medical University of South Carolina Phase 4 2016-06-01 The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease associated Pulmonary Arterial Hypertension (CTD-PAH).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Opsumit

Condition Name

Condition Name for Opsumit
Intervention Trials
Healthy Subjects 2
Healthy 2
Pulmonary Arterial Hypertension 2
Chronic Thromboembolic Pulmonary Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Opsumit
Intervention Trials
Hypertension 4
Familial Primary Pulmonary Hypertension 2
Hypertension, Pulmonary 2
Anemia, Sickle Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Opsumit

Trials by Country

Trials by Country for Opsumit
Location Trials
United States 52
Germany 3
Canada 2
Australia 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Opsumit
Location Trials
Texas 2
Massachusetts 2
California 2
Illinois 2
Louisiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Opsumit

Clinical Trial Phase

Clinical Trial Phase for Opsumit
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Opsumit
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 3
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Opsumit

Sponsor Name

Sponsor Name for Opsumit
Sponsor Trials
Actelion 6
Boston University 1
Janssen Research & Development, LLC 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Opsumit
Sponsor Trials
Industry 7
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Johnson and Johnson
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.